Retinoids ameliorate insulin resistance in a leptin-dependent manner in mice

Hiroyuki Tsuchiya1, Yoshito Ikeda, Yu Ebata

  • 1Department of Biophysical Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan. tsuchiya@mb.kyoto-phu.ac.jp

Abstract

Insights

Retinoids, like all-trans-retinoic acid (ATRA), enhance insulin sensitivity by activating hepatic leptin signaling. This mechanism improves insulin resistance in models of nonalcoholic fatty liver disease (NAFLD) and suggests retinoids as potential treatments.

Area of Science:

  • Hepatology
  • Endocrinology
  • Molecular Biology

Background:

  • Dominant-negative retinoic acid receptor alpha (RARα) in liver causes steatohepatitis and liver tumors in mice.
  • Diminished insulin-like growth factor-1 suggests insulin resistance may underlie this condition.

Purpose of the Study:

  • To investigate the effects of retinoids on insulin resistance.
  • To elucidate the mechanisms by which retinoids influence insulin sensitivity.

Main Methods:

  • Dietary administration of all-trans-retinoic acid (ATRA) to C57BL/6J (NAFLD model) and KK-A(y) mice.
  • Assessment of insulin sensitivity, leptin signaling pathway proteins (STAT3, JAK2), and leptin receptor (LEPR) expression.
  • In vitro experiments using ATRA and a selective RARα/β agonist (Am80).

Main Results:

  • ATRA improved insulin sensitivity in NAFLD and KK-A(y) mice, correlating with STAT3 and JAK2 activation.
  • The effect was absent in leptin-deficient ob/ob mice, highlighting the role of leptin signaling.
  • ATRA upregulated hepatic LEPR expression and, in vitro, directly induced LEPR gene expression via RARα, enhancing STAT3 and insulin signaling.

Conclusions:

  • Retinoids activate hepatic leptin signaling, enhancing insulin sensitivity through an unrecognized mechanism.
  • This action was observed in two mouse models of insulin resistance.
  • Retinoids show potential for treating nonalcoholic fatty liver disease (NAFLD) associated with insulin resistance.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...